Giving u full information about a patient patient symptoms -- 1. fatigue exertional 2. edema in leg and face 3. dyspnea after work 4. chest pain History of patient - Hypertension for past 10 year during diagnostic ( now 10+5 = 15 year) Gender female Diagnosis age 40 Eco report at diagnosis time Tapse 29 Pasp 43 Tr gradient 40 Rv function and size normal Ntprobnp 762 Bilateral hazzi include cosphoteric angle in x ray of PA Rap 3 E/e' 8 ivsd 11.6 La (ap) 40mm Treatment - Slidanfil 2 time daily ( continue till now) Diuretic ( for 2 year) And multiple hypertension medicine After 6 month Edema gone completely ( edema gone within 1 month -- and 3-4 kg weight loss) Ntprobnp reduce to 100 Tr gradient reduce to 34 Rap Pasp 37 La 37 After 2 year Ntprobnp 200 something Pasp 42 E/e 9 ivsd 9 La 36 After 3.5 years Ntprobnp 100 Tr gradient 27 Pasp 30 Rap 3 E/e 7 Ivsd 8-9 La 39 After 5 year E/e 8 Ntprobnp 100 Tr gradient 27 Pasp 30 Rv size and functions normal Tapse 26 Ivsd 9 Rap 3 La 37 Current symptoms -- fatigue after work ( though less than before) Sligh shortness of breath after work.. Tell.me which group of pulmonary hypertension it is
Reading File
Searching the Web
pulmonary hypertension group 2 left heart disease diastolic dysfunction classification ESC 2022
Finding Sources
Finding Sources
Reading File
Reading File
I have all the information needed. Here is a thorough clinical breakdown:
This Patient Has Group 2 Pulmonary Hypertension - PH Associated with Left Heart Disease (PH-LHD)
Specifically: Group 2.1.1 - Heart Failure with Preserved Ejection Fraction (HFpEF)
Why Group 2, Not Group 1?
The key distinguishing feature here is that the PH is driven by the left heart, not by primary pulmonary vascular disease. Let me walk through every data point:
Left Heart Disease Evidence (the cause)
| Finding | Value | Interpretation |
|---|---|---|
| IVSd at diagnosis | 11.6 mm | Concentric LV hypertrophy from longstanding hypertension |
| LA (AP) | 40 mm | Left atrial enlargement - elevated LA filling pressure |
| E/e' | 8-9 | Elevated - indicates LV diastolic dysfunction (Grade I-II) |
| NTproBNP | 762 pg/mL | Elevated - left heart wall stress |
| Hypertension | 15 years | Classic cause of diastolic dysfunction / HFpEF |
| Bilateral haziness + costophrenic angle blunting on PA CXR | Present | Pulmonary venous congestion / pleural effusions |
| Response to diuretics | Edema resolved, 3-4 kg weight loss, NTproBNP dropped to ~100 | Classic HFpEF response - fluid offloading |
The IVSd (interventricular septum thickness in diastole) of 11.6 mm is diagnostic of LV hypertrophy. Combined with a hypertensive history of 15 years, enlarged LA, and elevated E/e', this patient has diastolic dysfunction from hypertensive heart disease - the textbook substrate for HFpEF.
Why the PASP Was Elevated
In Group 2 PH, the sequence is:
Hypertension → LV hypertrophy + diastolic dysfunction → elevated LV end-diastolic pressure → elevated LA pressure → pulmonary venous hypertension → elevated PASP
This is called isolated post-capillary PH (IpcPH) - the pulmonary pressure is elevated purely because the left-sided filling pressures are backed up.
- PASP at diagnosis: 43 mmHg (mildly-moderately elevated)
- TR gradient: 40 mmHg - consistent
- RAP: 3 mmHg (normal - RV not under chronic severe stress)
- TAPSE: 29 mm (normal RV function)
RV was normal in size and function throughout - this is very characteristic of Group 2 early PH, where the RV has not yet remodeled, unlike Group 1 PAH where the RV is typically dilated and hypertrophied at presentation.
The Treatment Response Confirms Group 2
| Timepoint | PASP | NTproBNP | TR Gradient | LA |
|---|---|---|---|---|
| Diagnosis | 43 mmHg | 762 | 40 | 40 mm |
| 6 months | 37 mmHg | ~100 | 34 | 37 mm |
| 2 years | 42 mmHg | ~200 | - | 36 mm |
| 3.5 years | 30 mmHg | ~100 | 27 | 39 mm |
| 5 years | 30 mmHg | ~100 | 27 | 37 mm |
The PASP tracked downward with treatment of the underlying left heart disease. This is pathognomonic of Group 2 - treating the upstream left heart problem relieves the pulmonary pressure. In Group 1 PAH, diuretics alone would not reduce PASP like this.
Sildenafil (a PDE-5 inhibitor) was used, which is actually not standard for Group 2 PH per current ESC/ERS 2022 guidelines - it is approved for Group 1. Its use here may have contributed pulmonary vasodilation on top of the diuretic benefit, which is why some clinicians trial it in Group 2 patients with a combined post- and pre-capillary component (CpcPH). The bulk of the improvement, however, is explained by the diuretic offloading the left heart.
Why NOT Group 1 (PAH)?
Group 1 PAH is excluded because:
- Evidence of left heart disease (hypertension, LV hypertrophy, diastolic dysfunction)
- No features of connective tissue disease, HIV, congenital heart disease, portal hypertension (Group 1 associated causes)
- PASP responded to diuretics and left heart treatment
- RV remained normal in size and function - PAH typically causes RV dilation over time
- Older female with longstanding hypertension is the archetypal HFpEF profile (Group 2)
Why NOT Group 3 or 4?
- Group 3 (lung disease/hypoxia): No history of COPD, ILD, sleep apnea, or smoking mentioned
- Group 4 (CTEPH): No history of pulmonary embolism or risk factors
Current Status at 5 Years
The patient now has:
- PASP 30 mmHg (near-normal range; normal PASP is <40 mmHg, or <35-37 mmHg by strict criteria)
- NTproBNP ~100 (well-controlled)
- TAPSE 26 (normal)
- RV size and function normal
- Mild residual symptoms (fatigue and slight dyspnea on exertion)
She is in a good clinical response state. The residual exertional symptoms are likely from the underlying HFpEF diastolic dysfunction and deconditioning, not from ongoing significant PH.
Summary
Group 2 PH - Heart Failure with Preserved Ejection Fraction (HFpEF-PH) Subtype: Isolated post-capillary PH (IpcPH) secondary to hypertensive heart disease with LV diastolic dysfunction
This is the most common form of PH overall, accounting for 65-80% of all PH cases per the 2022 ESC/ERS Guidelines. The management target is the underlying left heart disease (blood pressure control, diuretics for congestion), not pulmonary vasodilators per se.
- Textbook of Clinical Echocardiography, Table 9.3 - Clinical-Echo Correlates for Each Cause of PH
- Fishman's Pulmonary Diseases and Disorders - Clinical Classification of PH, Table 97-1
Age is not 55.. Patient current age 45.. at the age of 30 she develop hypertension..at the age of 40 ph ..and now 45
Thank you for the correction. The age clarification actually makes this case more interesting clinically, not less. Here is the updated picture:
Corrected Timeline
| Age | Event |
|---|---|
| 30 | Hypertension diagnosed |
| 40 | PH diagnosed (after 10 years of hypertension) |
| 45 | Current age (5 years after PH diagnosis) |
Does the Group 2 Diagnosis Change?
No - it remains Group 2 PH (HFpEF-PH). The age correction does not change the classification. Here is why:
The Young Age Actually Raises a Red Flag Worth Addressing
At age 40, developing PH in a female is an age range where Group 1 PAH is also a concern - since PAH typically affects younger females. So this is a fair question: could it be Group 1 misclassified as Group 2?
The answer is still no, and here is why each finding points away from Group 1:
Ruling Out Group 1 PAH in a 40-year-old Female
| Feature | This Patient | Typical Group 1 PAH |
|---|---|---|
| IVSd 11.6 mm | LV hypertrophy present | Normal LV wall thickness |
| E/e' 8-9 | Diastolic dysfunction | Normal diastolic function |
| LA 40 mm | LA enlarged | Normal LA size |
| Bilateral haziness + costophrenic angle blunting | Pulmonary venous congestion | Not typical at presentation |
| PASP 43 mmHg | Mild-moderate | Usually much higher (60-100+ mmHg) in Group 1 |
| RV size and function | Normal TAPSE 29, normal RV | RV typically dilated/hypertrophied |
| NTproBNP 762 | Modestly elevated | Usually much higher in Group 1 |
| Response to diuretics | PASP fell 43→37, NTproBNP 762→100 | Diuretics alone would NOT reduce PASP |
| 10 years of hypertension before PH | Classic substrate | No prior cardiac disease |
The LV hypertrophy (IVSd 11.6 mm) + diastolic dysfunction + LA enlargement in the setting of 10 years of untreated or poorly controlled hypertension in a 40-year-old is the direct mechanistic cause of her PH. This is not coincidental.
Why Hypertension at Age 30 Matters
Hypertension starting at age 30 is early-onset, and over 10 years it caused:
- Concentric LV remodeling (IVSd 11.6 mm)
- LV diastolic stiffness (elevated E/e', elevated NTproBNP)
- LA pressure chronically elevated → LA dilatation (40 mm)
- Pulmonary venous pressure chronically elevated → PASP 43 mmHg
This is a 10-year hypertensive heart disease trajectory producing secondary PH - textbook Group 2.
The 5-Year Follow-up Seals It
After treating left heart disease (antihypertensives + diuretics), at age 45:
- PASP dropped from 43 → 30 mmHg
- NTproBNP from 762 → ~100 pg/mL
- IVSd thinned slightly from 11.6 → 8-9 mm (LV reverse remodeling with BP control)
- LA reduced from 40 → 37 mm
LV reverse remodeling - the septum thinning and LA shrinking over 5 years - is only possible when you treat the cause. This is the clearest proof that her PH was driven by the left heart.
Final Answer (Unchanged in Classification, Enriched in Context)
Group 2.1.1 - PH due to Heart Failure with Preserved Ejection Fraction (HFpEF) Cause: Early-onset hypertension at age 30 → LV hypertrophy + diastolic dysfunction → secondary pulmonary venous hypertension by age 40 Current status at age 45: Well-controlled, with evidence of LV reverse remodeling on treatment
The young age (40 at diagnosis) is what makes this case look like it could be Group 1, but the echocardiographic fingerprint of left heart disease and the treatment response make Group 2 the definitive answer.
This is a shared conversation. Sign in to Orris to start your own chat.